Simcere Pharmaceutical Group’s (SCR) MACD indicator has entered into bearish territory with a reading of -0.0599. The Zacks #4 Rank (“Sell”) stock decreased slightly to $9.34 in morning trade. The Zacks Consensus Estimate for the year ending 2010 has decreased by 1 cent over the past two months to 34 cents per share.
 
SIMCERE PHARMAC (SCR): Free Stock Analysis Report
 
Zacks Investment Research